C
CalciMedica, Inc.
CALCCIK 0001534133NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-29.56M
Total Assets
—
Equity
—
Shares Out
15.80M
Op. Cash Flow
$-21.18M
Business
CalciMedica, Inc. is a clinical-stage biopharmaceutical company developing therapeutics that target calcium release-activated calcium (CRAC) channels to treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its main product candidates include Auxora, an IV lipid nanoemulsion CRAC channel inhibitor containing zegocractin, and several orally‑available CRAC inhibitors in preclinical development. The company organizes operations around clinical development programs (acute pancreatitis with SIRS, AIPT, acute kidney injury with AHRF, acute respiratory failure/ARDS) and ongoing preclinical research for chronic inflammatory diseases. CalciMedica conducts clinical trials and pursues partnerships and commercialization through hospital, clinical and international distribution channels, primarily in the United States and select global markets.
Summary from filing dated 2025-03-27
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 15 | 14 | 16 | 8 | 19 | |
| General and administrative | 8 | 10 | 22 | 6 | 17 | |
| Total operating expenses | 23 | 24 | 38 | 14 | 36 | |
| Loss from operations | −23 | −24 | −38 | −14 | −36 | |
| Change in fair value of financial instruments | −6 | 9 | 3 | — | — | |
| Interest expense | −1 | 0 | — | — | — | |
| Interest income | 713,000 | 1 | — | — | — | |
| Other income | 268,000 | 0 | 550,000 | −28,000 | — | |
| Total other income (expense) | −6 | 11 | 4 | 6 | — | |
| Net loss | −30 | −14 | −34 | −8 | −36 | |
| Net loss per share - basic | −1.97 | −1.22 | −7.66 | −111.16 | −1.69 | |
| Net loss per share - diluted | −1.97 | −1.22 | −7.66 | −111.16 | −1.69 | |
| Weighted-average number of shares outstanding used in computing net loss per share - basic | 15 | 11 | 4 | 82,245 | 21 | |
| Weighted-average number of shares outstanding used in computing net loss per share - diluted | 15 | 11 | 4 | 82,245 | 21 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 12 | 8 | 6 | 1 | 13 | |
| Short-term investments | 1 | 11 | 6 | 0 | 50 | |
| Prepaid clinical trial expenses | 201,000 | 748,000 | 71,000 | — | — | |
| Other prepaid expenses and current assets | 259,000 | 248,000 | 296,000 | 254,000 | 3 | |
| Assets held for sale | 54,000 | 0 | — | — | — | |
| Total current assets | 14 | 20 | 12 | 2 | 67 | |
| Property and equipment, net | 50,000 | 119,000 | 167,000 | 147,000 | 2 | |
| Other assets | 11,000 | 10,000 | 413,000 | 1 | — | |
| Total assets | 14 | 20 | 12 | 3 | 69 | |
| Accounts payable | 1 | 2 | 1 | 3 | 527,000 | |
| Accrued clinical trial costs | 1 | 820,000 | 1 | 1 | — | |
| Accrued expenses | 290,000 | 866,000 | 1 | 572,000 | — | |
| Current portion, promissory note | 1 | 0 | — | — | — | |
| Total current liabilities | 4 | 4 | 4 | 5 | 4 | |
| Promissory note | 8 | 0 | — | — | — | |
| Warrant liability | 8 | 2 | 0 | 3 | — | |
| Total liabilities | 20 | 5 | 4 | 13 | 4 | |
| Commitments and contingencies (Note 8) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; no shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 0 | 0 | 0 | 0 | — | |
| Common stock, $0.0001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 15,437,410 and 13,481,917, issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 4,000 | 4,000 | 1,000 | 1,000 | 2,000 | |
| Additional paid-in capital | 183 | 174 | 154 | 40 | 234 | |
| Accumulated deficit | −189 | −160 | −146 | −112 | −169 | |
| Accumulated other comprehensive income | 0 | 4,000 | 2,000 | −37,000 | −16,000 | |
| Total stockholders' equity (deficit) | −7 | 14 | 8 | −71 | −64 | |
| Total liabilities and stockholders' equity (deficit) | 14 | 20 | 12 | 3 | 69 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −30 | −14 | −34 | −8 | −36 | |
| Stock-based compensation expense | 3 | 2 | 12 | 2 | 5 | |
| Depreciation | 46,000 | 58,000 | 58,000 | 300,000 | 500,000 | |
| Change in the fair value of warrant liability | 5 | −9 | −1 | −4 | — | |
| Change in the fair value of promissory note | 777,000 | 0 | — | — | — | |
| Promissory note issuance costs | 336,000 | 0 | — | — | — | |
| Transaction costs associated with warrants | 0 | 776,000 | 0 | — | — | |
| Accretion of discount on short-term investments | −345,000 | −608,000 | −145,000 | −319,000 | 58,000 | |
| Change in unrealized losses on investments | −1,000 | 0 | — | — | — | |
| Prepaid expenses, other current and non-current assets | 536,000 | −228,000 | 3 | −2 | 1 | |
| Accounts payable | −840,000 | 601,000 | −1 | 933,000 | −2 | |
| Accrued expenses and other liabilities | −319,000 | −868,000 | −2 | 1 | — | |
| Net cash used in operating activities | −21 | −21 | −26 | −12 | −32 | |
| Purchase of investments | −16 | −29 | −6 | −36 | −95 | |
| Maturity of investments | 25 | 25 | 15 | 64 | 106 | |
| Purchases of property and equipment | −28,000 | −8,000 | −78,000 | −4,000 | −488,000 | |
| Net cash provided by (used in) investing activities | 10 | −4 | 9 | −4,000 | 11 | |
| Proceeds from issuance of common stock, net of issuance costs | 8,000 | 28 | 10 | — | — | |
| Proceeds from exercise of stock options | 25,000 | 20,000 | 0 | — | 695,000 | |
| Proceeds from issuance of promissory note, net | 10 | 0 | — | — | — | |
| Proceeds from issuance of common stock from ATM Facility, net of issuance costs | 6 | 49,000 | 246,000 | 18,000 | — | |
| Net cash provided by financing activities | 15 | 28 | 21 | 8 | 695,000 | |
| Net increase in cash and cash equivalents | 4 | 2 | 4 | −3 | −20 | |
| Cash paid for interest | 1 | 0 | — | — | — | |
| Financing costs included in accounts payable and accrued expenses | 3,000 | 78,000 | 45,000 | — | — | |
| Equipment purchases included in accounts payable | 3,000 | 0 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro